Spinal-Fluid vaccine targets breast cancer cells in the brain

NCT ID NCT07694986

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This study tests a dendritic cell vaccine given directly into the spinal fluid for people with breast cancer that has spread to the lining of the brain and spinal cord (leptomeningeal disease). The vaccine is combined with either trastuzumab (for HER2-positive cancer) or nivolumab (for HER2-negative cancer). The goal is to find the safest dose and see if the treatment can help people live longer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
dendritic cell vaccine (cDC1) given into the spinal fluid, plus trastuzumab or nivolumab
What this could lead to
If successful, this approach could offer a new treatment option for people with breast cancer that has spread to the lining of the brain and spinal cord, a condition with very few effective therapies.
What could go wrong
This is an early-phase trial with only 30 participants, so results may not apply to everyone. The treatment involves injections into the spinal fluid, which carries risks like infection or nerve damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Moffitt Cancer Center

    RECRUITING

    Tampa, Florida, 33612, United States

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.